Longeveron jumps on FDA's 'RMAT' tag for Alzheimer's therapy

Longeveron

10/07/2024 13:14

** Cell therapy developer Longeveron's  LGVN.O  shares rise
~15% to $3.29 premarket
    ** Company says U.S. FDA has granted Regenerative Medicine
Advanced Therapy (RMAT) designation to its mild Alzheimer's
therapy Lomecel-B 
    ** RMAT designation expedites development and review of
regenerative medicine therapies and offers sponsor companies
early interactions with FDA
    ** As of last close, stock down 78.9% YTD

 (Reporting by Christy Santhosh)
 ((Christy.Santhosh@thomsonreuters.com))